EP Show – March 2003 Heart Failure The EP Show: New approaches to heart failure Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.

Slides:



Advertisements
Similar presentations
Presenter Disclosure Information
Advertisements

EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
CARDIOVASCULAR EFFECTS OF ANTHRACYCLINE-LIKE CHEMOTHERAPY AGENTS JOHN N. HAMATY FACC, FACOI.
Natale MARRAZZO Francesco SOLIMENE Quando la CRT-P può bastare?
Update on Indications for Cardiac Resynchronization Therapy Maria Rosa Costanzo, M.D., F.A.C.C., F.A.H.A. Medical Director, Midwest Heart Specialists-Advocate.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Purpose To determine whether metoprolol controlled/extended release
MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.
Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.
Journal Review-CRT Dr Pradeep Sreekumar Senior Resident Cardiology.
Prepared by : Nehad J. Ahmed.  Heart failure, also known as congestive heart failure (CHF), means your heart can't pump enough blood to meet your body's.
© 2000 Heart Failure Society of America, Inc.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Fast & Easy ECGs, 2nd E – A Self-Paced Learning Program
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
JONATHAN MANT, MD; ABDALLAH AL-MOHAMMAD, MD; SHARON SWAIN, BA, PHD; AND PHILIPPE LARAMEE,DC,MSC, FOR THE GUIDELINE DEVELOPMENT GROUP CHRIS FONTIMAYOR MS-III.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
EP Show – Aug 2003 ICDs – Primary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
La selezione dei pazienti candidati alla Terapia Resincronizzante Cardiaca M Cristina Porciani Firenze “Incontri Pitagorici di Cardiologia 2010” “Πυθαγόρειοι.
Renal function and clinical outcomes of patients undergoing ICD and CRTD implantation- Data from the Israeli ICD Registry Alon Eisen, Mahmoud Souleiman,
Clinical Characteristics and Outcomes of Elderly Patients Treated With ICD and CRTD in Real World Setting: Data From the Israeli ICD Registry M. Suleiman,
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Working Group of Heart Failure and Cardiac Function How to evaluate and treat dyssynchrony ? P Lancellotti, LA Piérard, Liège, BE.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
EP Show – April 2002 MADIT II The EP Show: MADIT II Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.
Integrating Monitoring into the Infrastructure and Workflow of Routine Practice Philip B. Adamson, MD Associate Professor of Physiology Director, The Heart.
Ablation: past, present, and future Dr Eric Prystowsky Director Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis Dr Mel Scheinman.
EP Show – December 2002 AFFIRM The EP Show: AFFIRM Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital The Care Group.
S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Case Studies The results presented in these case studies are specific to these individual patients. Patient results will vary, not every response is the.
EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical.
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
CRDAC Questions June 15, 2005 Antihypertensive drugs, with few exceptions, have no outcome claim in their labeling. This is inconsistent with their approval.
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
Q I A 12 Fast & Easy ECGs – A Self-Paced Learning Program Origin and Clinical Aspects of AV Heart Blocks.
SMMART-HF Surgery vs. Medical Treatment Alone for Patients with Significant MitrAl RegurgitaTion & Non-Ischemic Congestive Heart Failure Duke Heart Failure.
New Therapies Heather Kertland, PharmD. Eplerenone Ultrafiltration CRT Outline New Agents.
Heart Failure Devices: Staying Connected Lisa D. Rathman, MSN, CRNP, CCRN, CHFN The Heart Group of Lancaster General Health Lancaster, PA.
In the name of GOD 1. Treatment of End Stage Heart Failure Surgical Treatments Cardiac Resynchronization Treatment(CRT) 2.
Dr Eric Prystowsky Director Clinical Electrophysiology Laboratory St Vincent Hospital, Indianapolis Dr Leslie Saxon Chief, Electrophysiology Laboratory.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.
Late Open Artery Hypothesis Jason S. Finkelstein, M.D. Tulane University Medical Center 2/24/03.
CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Cardiac-Resynchronization in Moderate Heart Failure Christopher Hughes PA-S Pacific University School of Physician Assistant Studies, Hillsboro, OR USA.
Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Impact of QRS Duration on Clinical Event Reduction.
CRT Overview This lecture is intended to give a basic overview of HF to include: -General knowledge of the cardiac cycle and how a normal heart should.
RCTs in Cardiac Resynchronization Therapy StudyPtNYHALVEFLVEDDRhythmQRSICD PATH-CHF41III,IV≤35%AnySR≥120N MUSTIC58III≤35%≥60SR≥150N MIRACLE453III,IV≤35%≥55SR≥130N.
Ridha Chakeer MD PGY3. Objectives: Approximately 5.2 million Americans are affected  accounts for more than 3 million outpatient visits to primary care.
Date of download: 11/11/2016 Copyright © The American College of Cardiology. All rights reserved. From: Targeted Left Ventricular Lead Placement to Guide.
BLOCK HF Study Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block – Preliminary Results.
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
– р<0.05 between baseline
Kuznetsov VA, Soldatova AM, Krinochkin DV, Enina TN
Optimal Pacing for Right Ventricular and Biventricular Devices
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
David D. Berg et al. JACC 2018;71:
The EP Show: CMS reimbursement decision for ICDs
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

EP Show – March 2003 Heart Failure The EP Show: New approaches to heart failure Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, IN Leslie Saxon MD Director of Electrophysiology University of Southern California Los Angeles, CA Gary Francis MD Director of Coronary Care Unit Cleveland Clinic Foundation Cleveland, OH

EP Show – March 2003 Heart Failure Pharmacologic approach Dramatic changes in the past 15 to 20 years ACE inhibitors and beta blockers are the cornerstone of therapy Loop diuretics, spironolactone, and various adjunctive therapies remain Francis

EP Show – March 2003 Heart Failure Dosing Dosing in real practice rarely reflects dosing in controlled clinical trials Dosing should be titrated up gradually (over several weeks) Using higher doses than those used in trials is controversial; there is no strong data supporting higher doses Francis

EP Show – March 2003 Heart Failure Diastolic heart failure We currently have no trials to dictate practice in these patients In my practice I tend to treat these patients with diuretics (careful not to create a hypovolemic state) These patients respond to ACE inhibitors and beta blockers A regimen of ACE inhibitors, beta blockers, and diuretics seems to work Francis

EP Show – March 2003 Heart Failure Resynchronization therapy Epidemiological outcome studies showed bundle branch block had a negative impact on mortality Early 1990s: Heart failure patients with RV pacemakers didn't do very well Mid-1990s: The presence of bundle branch block worsens hemodynamics Pacing both ventricles simultaneously seemed to improve the hemodynamics Saxon

EP Show – March 2003 Heart Failure Pilot studies 3 biventricular pacing trials gained approval for resynchronization devices in the US MIRACLE InSync ICD CONTAK CD Resynchronization therapy is now indicated for NYHA class 3 patients with QRS delay Saxon

EP Show – March 2003 Heart Failure Functional improvement All resynchronization therapy studies showed improvement in functional status: Symptom status 6-minute walk Quality of life Peak oxygen consumption Modest reverse remodeling Saxon

EP Show – March 2003 Heart Failure Class 2 patients Therapy is labeled for class 3 patients, but the ICD trials did enroll class 2 patients Class 2 patients showed no significant improvement in symptoms but did show remodeling benefit Saxon

EP Show – March 2003 Heart Failure COMPANION: Enrollment Enrollment began in 1998, enrolled 1600 patients with QRS>120 ms P-R interval>150 ms Class 3 heart failure Hospitalization for heart failure in the past year

EP Show – March 2003 Heart Failure COMPANION: End points Patients were randomized to optimal medical therapy, cardiac resynchronization, or resynchronization with an ICD Trial stopped in November 2002: 20% reduction in all-cause mortality and all-cause hospitalization in both device groups 40% reduction in all-cause mortality in patients who received the combined resynchronization/ICD device

EP Show – March 2003 Heart Failure CARE-HF: Enrollment Enrollment began in 2001, enrolled 800 patients with NYHA class 3/4 18-month follow-up Randomized to resynchronization or optimal medical management

EP Show – March 2003 Heart Failure Resynchronization therapy It appears to meet the 3 goals of heart failure therapy Improves functional status Slows disease progression Improves mortality and hospitalization end points Saxon

EP Show – March 2003 Heart Failure Differing response Patients on cardiac resynchronization fall into 3 categories: Fabulous response, can improve up to 2 heart classes "Tweeners" who get some benefit but not as much as we would like 20% to 25% who don't respond at all Prystowsky

EP Show – March 2003 Heart Failure Nonresponders "This is the science that is going to keep the next generation of people busy." We don't understand the relationship between QRS delay and mechanical dysynchrony Saxon

EP Show – March 2003 Heart Failure Defining resynchronization We don't understand how to define resynchronization QRS delay correlates with ventricular size but does not predict clinical response No gold standard of measuring mechanical dysynchrony or resynchronization--we simply don't know what the best measure is Saxon

EP Show – March 2003 Heart Failure Lead location Are nonresponders the result of bad lead placement? Left bundle-branch block is an incredibly heterogeneous condition, and lead placement will be very patient specific You should be able to get response in 70% or so even without perfect lead placement Saxon

EP Show – March 2003 Heart Failure Optimal programming We could get better results just from optimal programming of AV delay New devices offer new options, but there is no established standard way to assess resynchronization In my lab we are using echo to follow patients and treating the instrument like a drug, altering the parameters and finding the best response Saxon

EP Show – March 2003 Heart Failure Increased expectations Like all therapies, we found something that works, and now we demand better and better results "I'm getting from your thoughts that we know the therapy works; we have a lot of fine-tuning to do." Prystowsky

EP Show – March 2003 Heart Failure Advancing the field Since market approval, > have been implanted in the US These devices and patients require a lot of attention; the science needs to be resolved "I've had several heart failure people come up to me and say, 'You know in the clinical trials our guys were getting results with implants of 70, 80, 90, 90- plus percent and now I think our results aren't as good." Saxon

EP Show – March 2003 Heart Failure Patient selection At what point do you send a patient for resynchronization therapy? It's not entirely clear, but the threshold for implantation is getting lower and lower We find about one third of patients don't get better or have no change We might accept those numbers if this were a drug Francis

EP Show – March 2003 Heart Failure Patient selection Candidates for resynchronization Class 3 patient on full therapy who is still clinically struggling Patients with late class 2 and possibly lower if we can refine the selection criteria Patients receiving modified Dor procedure who don't do well Francis

EP Show – March 2003 Heart Failure Patient dilemma Patient with class 3 heart failure who isn't doing as well as we would like IBCD QRS duration 140 ms EF 25% Is there any use for a biventricular pacemaker as opposed to a defibrillator in light of what we know about COMPANION?

EP Show – March 2003 Heart Failure Nonischemic cardiomyopathy "In most instances I would at least bring up the discussion of the defibrillator." Defibrillators have not yet proved benefit in patients with nonischemic cardiomyopathy At least 40% of patients in COMPANION had nonischemic cardiomyopathy As heart failure progresses, the etiology may become less relevant Saxon

EP Show – March 2003 Heart Failure Synchronization device alone There is a role for just synchronization therapy in advanced heart failure patients who have very poor outlook for 6-month survival Start with a resynchronization device and if they respond well put in an ICD It is no good if you put in an ICD, they don't get better, you give them lots of shocks and then have to take the ICD out Saxon

EP Show – March 2003 Heart Failure Pacemakers as prevention Could a pacemaker prevent class 2 patients from becoming class 3? Does the antiremodeling effect become permanent if you pace long enough? If there were permanence you could make an argument to use pacemakers in less-ill patients Francis

EP Show – March 2003 Heart Failure Long-term pacing Follow-up on the chronic trials goes out to 1 year The remodeling appears to be a direct effect of pacing Out to 1 year, volumes improve but mass does not change We don't see the same structural changes as with drugs, but it may happen in the future Saxon

EP Show – March 2003 Heart Failure Pacing damage Pacing just the right ventricle may alter the heart in a negative way The recognition that we can create dysynchrony that hurts the ventricle should make us rethink pacing just the right side Francis

EP Show – March 2003 Heart Failure Pacing the left ventricle Patients with significant mitral regurgitation can be risky to pace just the right ventricle Especially ones with an AV junction ablation can end up in the OR Now that we have other options, we should think things through before just putting in an RV lead Prystowsky

EP Show – March 2003 Heart Failure Who follows these patients? Electrophysiologists are putting the devices in, but should they follow up? Will heart failure specialists have to learn how to implant these devices? How would you develop a program for training for the future? Prystowsky

EP Show – March 2003 Heart Failure Busy EP doctors Electrophysiologists are just too busy to see these patients It's unrealistic to expect them to come out of the lab 1 or 2 days a week to see these patients We should expect a loose affiliation between heart failure specialists and EPs Francis

EP Show – March 2003 Heart Failure Coordinating care We scheduled the pacemaker clinic with the heart failure clinic to allow better coordination of care We trained heart failure fellows in EP for 3 or 4 months to give them an understanding of the device area EPs could subspecialize into complex ablation and device specialists who do implantation and follow-up Saxon

EP Show – March 2003 Heart Failure Limited resources Electrophysiologists don't know enough about the pharmacologic management of these patients In a small group, you don't have a specialist who can focus on the medical management This will have to be a part of training in the future because these devices are put in on top of medical therapy Prystowsky

EP Show – March 2003 Heart Failure New pharmacological approaches Additional neurohormonal antagonist agents have not proved effective TNF-alpha blockers weren't effective Omapatrilat wasn't effective There is a move to comorbid conditions Francis

EP Show – March 2003 Heart Failure Comorbid conditions 15% to 20% of heart failure patients are anemic 2 companies launching trials with erythropoeitin to address the anemia Also a move to develop drugs to augment renal function Arginine vasopressin antagonists Adenosine antagonists Francis

EP Show – March 2003 Heart Failure Summary Initial approach should be to optimize pharmacologic treatment of heart failure patients Patients who remain in class 3 failure with significant QRS duration are candidates for a resynchronization device, probably with an ICD Once you have a device you need to be managed carefully by specialists Prystowsky

EP Show – March 2003 Heart Failure The EP Show: New approaches to heart failure Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis, IN Leslie Saxon MD Director of Electrophysiology University of Southern California Los Angeles, CA Gary Francis MD Director of Coronary Care Unit Cleveland Clinic Foundation Cleveland, OH